evidence rnai humans systemically administered sirna via targeted nanoparticles 
therapeutics designed engage rna interference rnai pathways potential provide new major ways imparting therapy patients12 long double-stranded rnas first shown mediate rnai caenorhabditis elegans3 potential use rnai human therapy demonstrated finding small interfering rnas sirnas; approximately -base-pair double-stranded rna can elicit rnai mammalian cells without producing interferon response4 present conducting first in-human phase clinical trial involving systemic administration sirna patients solid cancers using targeted nanoparticle delivery system provide evidence inducing rnai mechanism action human delivered sirna tumour biopsies melanoma patients obtained treatment show presence intracellularly localized nanoparticles amounts correlate dose levels nanoparticles administered knowledge first systemically delivered nanoparticles kind furthermore reduction found specific messenger rna m2 subunit ribonucleotide reductase rrm2 protein rrm2 levels compared pre-dosing tissue notably detect presence mrna fragment demonstrates sirna-mediated mrna cleavage occurs specifically site predicted rnai mechanism patient received highest dose nanoparticles together data demonstrate sirna administered systemically human can produce specific gene inhibition reduction mrna protein rnai mechanism action 
